Home
Parmax Pharma Ltd Share Price History
Parmax Pharma Ltd
BSE : 21 Feb, 2025
42.93-0.9 (-2.1%)
Prev Close
43.8
Open Price
44.7
Bid Price (QTY)
-
Offer Price (QTY)
-
Volume
1303
Today's High / Low
44.7 / 42.8
52 WK High / Low
54.0 / 24.2
Market Price of Parmax Pharma Ltd
1M
1Y
3Y
5Y
Monitoring Parmax Pharma Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.
History Market Price
| Date | Price | Open | High | Low |
|---|
Returns Comparison
1W
1M
3M
6M
1Y
3Y
5Y
10Y
Growth Parameters
| Parameter |  2017 |
|---|---|
| Sales (Cr.) | 0 |
| Sales YoY Gr. | - |
| Adj EPS | 0 |
| YoY Gr. | - |
| Net Profit (Cr.) | -0 |
| BVPS | 10.24 |
Key Financial Parameters
| Parameter | 2017 |
|---|---|
| Return on Capital Emp. % | 0 |
| Op. Profit Mgn % | 0 |
| Net Profit Mgn % | 0 |
| Debt to Equity % | 0.16 |
Latest Shareholding
Promoters Holdings Over Time
About Parmax Pharma Ltd
- Incorporated in Nov.'94, Parmax Pharma Ltd (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara.
- The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax's pharmaceutical operations. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc.
- The Company then discontinued their business activities for few years due to various reasons.
- Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA.
Popular Search
FAQs for Parmax Pharma Ltd Share Price History
What are the key events that typically impact Parmax Pharma Ltd's share price history?
Key events that impact Parmax Pharma Ltd’s share price history include quarterly earnings releases, product launches, leadership changes, economic policies, and geopolitical developments.
How do stock splits affect Parmax Pharma Ltd's share price history?
Stock splits reduce the nominal price of Parmax Pharma Ltd's shares by increasing the number of outstanding shares, which typically makes the stock more accessible to a broader range of investors. Although the total market value of the company remains unchanged after the split, the split can affect investor perception and liquidity, potentially influencing the share price in the longer term.
How do dividends impact the share price history of Parmax Pharma Ltd?
Dividends can influence Parmax Pharma Ltd's share price history by typically causing a temporary dip on the ex-dividend date, as the stock price often adjusts to reflect the dividend payout. Over time, the impact of dividends on the share price may be offset by the company's overall financial performance and market conditions.
How do corporate announcements affect Parmax Pharma Ltd’s share price history?
Corporate announcements such as mergers, acquisitions, or strategic shifts can lead to significant price changes. Any optimistic development news on Parmax Pharma Ltd generally boosts the company’s share price, whereas negative news can lead to a decline in share price.
How can I use technical analysis to understand Parmax Pharma Ltd’s share price history?
To understand Parmax Pharma Ltd’s share price history using technical analysis, examine charts for patterns such as trends, support, and resistance levels, and apply indicators like moving averages or Relative Strength Index (RSI) to gauge potential future movements. Analyze historical data to identify recurring trends and signals that might suggest how the share price could behave under similar conditions.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
